Table 3 Clinical characteristics at baseline evaluation of the three study groups
Variables | At-home n = 33 | Outpatient n = 23 | Control n = 29 |
|---|---|---|---|
Dyspnea - MRC 0 | 8 (24.2) | 6 (26.1) | 8 (27.6) |
Dyspnea - MRC 1 | 9 (27.3) | 8 (34.8) | 8 (27.6) |
Dyspnea - MRC 2 | 10 (30.3) | 5 (21.7) | 10 (34.5) |
Dyspnea - MRC 3 | 6 (18.2) | 4 (17.4) | 2 (6.9) |
Dyspnea - MRC 4 | 0 (0) | 0 (0) | 1 (3.4) |
Cough | 31 (93.9) | 20 (86.9) | 26 (89.6) |
Secretion | 12 (36.4) | 8 (34.8) | 11 (37.9) |
Wheezing | 26 (78.8) | 15 (65.2) | 20 (69.0) |
Post-bronchodilator spirometry | |||
FVC (L) | 2.19 ± 0.71 | 2.51 ± 0.82 | 2.22 ± 0.55 |
FVC (%) | 68.7 ± 30.2 | 79.1 ± 30.0 | 69.9 ± 28.0 |
FEV1 (L) | 1.31 ± 0.76 | 1.32 ± 0.68 | 0.99 ± 0.46 |
FEV1 (%) | 47.5 ± 23.3 | 51.5 ± 23.9 | 41.4 ± 18.4 |
FEV1/FVC (%) | 69.1 ± 21.8 | 65.1 ± 24.5 | 59.2 ± 20.6 |
COPD stage | |||
GOLD I | 4 (12.1) | 2 (8.7) | 2 (6.9) |
GOLD II | 8 (24.2) | 10 (43.5) | 6 (20.7) |
GOLD III | 11 (33.3) | 5 (21.7) | 13 (44.8) |
GOLD IV | 10 (30.3) | 6 (26.1) | 8 (27.6) |
BODE | 4 (0-7) | 4 (0-8) | 4 (1-9) |